Peritoneal Dissemination and Malignant Ascites in Duodenal Cancer Successfully Treated With Adoptive Cell Therapy Using WT1- and MUC1-Pulsed Dendritic Cells and Activated T Cells With No Adverse Effects: A Case Report.

Autor:	Yagawa Y; Department of Immunotherapy, Bio-Thera Clinic, Tokyo, JPN., Kobayashi Y; Department of Immunotherapy, Bio-Thera Clinic, Tokyo, JPN., Fujita I; Department of Surgery, Ebara Hospital, Tokyo, JPN., Watanabe M; Department of Surgery, Toho University Ohashi Medical Center, Tokyo, JPN., Koido S; Internal Medicine, The Jikei University School of Medicine, Tokyo, JPN., Sugiyama H; Department of Cancer Immunology, Osaka University Graduate School of Medcine, Osaka, JPN., Tanigawa K; Department of Immunotherapy, Bio-Thera Clinic, Tokyo, JPN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Nov 30; Vol. 16 (11), pp. e74834. Date of Electronic Publication: 2024 Nov 30 (Print Publication: 2024).
DOI:	10.7759/cureus.74834
Abstrakt:	A satisfactory treatment for the dissemination of duodenal cancer has not yet been established. We describe a case of peritoneal dissemination and malignant ascites in duodenal cancer that was successfully treated with adoptive cell therapy with no adverse effects. A 72-year-old Japanese male patient with primary duodenal cancer with distal lymph node metastases received chemotherapy with S-1, an oral pyrimidine fluoride - derived agent, and oxaliplatin after gastrojejunal bypass, which resulted in tumor shrinkage; however, peritoneal dissemination developed. Despite the administration of a second-line chemotherapy regimen comprising irinotecan, peritoneal dissemination, malignant ascites, and cachexia continued to progress, ultimately resulting in the failure of chemotherapy. He then received adoptive cell therapy with Wilms' tumor 1 (WT1)- and mucin 1 (MUC1) peptide-pulsed dendritic cells (WT1/MUC1-DC) and CD3-activated T lymphocytes (CAT). Following the administration of this treatment eight times per week, the patient's symptoms and malignant ascites surrounding his cancer disappeared. He developed no adverse effects from this treatment and was able to resume his usual activities without any symptoms. He has continued this treatment every few months as maintenance therapy and has been free of relapse for 54 months. This case suggests a possible beneficial effect of adoptive cell therapy with WT1/MUC1-DC and CAT for peritoneal dissemination and malignant ascites in duodenal cancer. Competing Interests: Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Bio-Thera Clinic Authorized Committee for Regenerative Medicine issued approval NB3140004. This study was conducted in accordance with the basic principles of the Declaration of Helsinki. Following the opinion of an Accredited Committee for Regenerative Medicine, etc. accredited by the Regional Health and Welfare Bureau (Bio-Thera Clinic Authorized Committee for Regenerative Medicine: NB3140004), a regenerative medicine provision plan was submitted to the Minister of Health, Labor and Welfare. The approved plan and facilities providing regenerative medicine include cancer vaccine therapy using tumor antigen-labeled dendritic cell vaccine (PC3150005) and activated lymphocyte therapy (PC3150004). Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Yagawa et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu